No Data
Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital Not Reflecting Well On The Business
Yixintang Pharmaceutical Group (SZSE:002727) Stock Falls 4.9% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
BAIYUNSHAN PH announced its performance for 2024, with a net income of approximately 2.835 billion yuan, a decrease of 30.09% compared to the previous year.
BAIYUNSHAN PH (00874) announced its 2024 performance, with revenue of approximately 74.993 billion yuan, a year-on-year decrease of 0.69%; the Net income attributable to shareholders is approximately 2.835 billion yuan, a year-on-year decrease of 30.09%; the non-recurring Net income is approximately 2.356 billion yuan, a year-on-year decrease of 35.18%; the basic EPS is 1.744 yuan, and a proposed Cash dividend of 0.40 yuan per share. The announcement stated that the main reasons for the year-on-year decline in performance are: during this reporting period, the group's main Business sectors' operating performance was continuously affected by factors such as insufficient effective demand, accelerated industry transformation, changes in industry policies, and fierce market competition.
Yixintang Pharmaceutical (002727.SZ): Currently has launched Medical clinics and health maintenance related Business.
Gelonghui reported on March 11 that Yixintang Pharmaceutical (002727.SZ) stated on its investor interaction platform that the company primarily engages in Pharmaceutical retail chain business, has currently developed Medical clinic and health-related services, and in the future, it will deeply cultivate the big health industry according to its Global Strategy.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Yixintang Pharmaceutical (002727.SZ): First buyback of 0.335 million shares.
On February 18, GeLongHui reported that Yixintang Pharmaceutical (002727.SZ) announced that on February 18, 2025, the company repurchased 335,200 shares through a dedicated securities account for share buybacks using centralized competitive trading, accounting for 0.06% of the company's total share capital. The highest Fill Price was 12.92 yuan per share, the lowest Fill Price was 12.68 yuan per share, and the total amount of the transaction was 4,286,868 yuan (excluding transaction fees). This buyback complies with relevant laws and regulations and aligns with the established share repurchase plan.
4.8% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Yixintang Pharmaceutical Group (SZSE:002727) Shareholders Over That Period
